Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE M 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE M 300.
ISOVUE-128 vs ISOVUE-M 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Iopamidol is a nonionic, low-osmolality iodinated contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing the visibility of vascular structures and organs during imaging procedures. It acts by absorbing X-rays due to the high atomic number of iodine.
Adult: 50-200 mL (0.5-2.0 mL/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
1.0-2.0 mL/kg intravenous bolus for CT imaging up to a total of 150 mL per procedure; intra-arterial dosing varies by procedure, typical adult dose 30-60 mL per injection.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 mL/min).
Terminal elimination half-life: approximately 2 hours (range 1.5–2.5 hours). Normal renal function; prolonged in renal impairment.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Primarily renal excretion via glomerular filtration; unchanged drug: >95% excreted in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Category C
Category C
Contrast Media
Contrast Media